

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (“**Director(s)**”) of Raily Aesthetic Medicine International Holdings Limited (the “**Company**”) announces that Dr. Lin Hai (“**Dr. Lin**”) has been appointed as an Independent Non-Executive Director of the Company, with effect from 27 March 2026.

The Board further announces that Mr. Cao Dequan (“**Mr. Cao**”) has resigned as an Independent Non-Executive Director with effect from 27 March 2026. Mr. Cao will not hold any positions in the Company after his resignation, which shall be of immediate effect.

#### **(1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board is pleased to announce that with effect from 27 March 2026, Dr. Lin has been appointed as the Independent Non-Executive Director, Chairman of the Remuneration Committee, Member of the Audit Committee, Member of the Nomination Committee and Member of the Strategic Investment Committee of the Company.

Dr. Lin, aged 43, is currently a researcher and doctoral Supervisor at the College of Biomedical Engineering of Sichuan University (四川大學生物醫學工程學院) and the National Engineering Research Center for Biomaterials (國家生物醫學材料工程技術研究中心). He is a prominent expert in the biomedical field, currently serving as a technical review expert for medical devices at the National Medical Products Administration (NMPA) of the PRC (國家藥品監督管理局).

Dr. Lin holds several key leadership positions in professional organizations, including the vice chairman of the Regenerative Biomaterials Branch (整復生物材料分會) of the Chinese Society for Biomaterials (中國生物材料學會), and the deputy director of the Shanxi Key Laboratory of Functional Proteins (功能蛋白山西省重點實驗室).

Dr. Lin has extensive experience in the research, product development, and clinical application of tissue-inductive biomaterials and medical implants, with a particular focus on natural polymers such as collagen (including recombinant collagen) and hyaluronic acid. Throughout his career, he has led numerous national key research projects, including special projects under the 13th and 14th Five-Year National Key R&D Programs of China. He has published over 30 SCI-indexed papers, filed more than 25 national invention patents with successful commercialization records, and served as a core drafter for multiple industry and group standards.

Dr. Lin obtained a Bachelor's degree in Light Chemical Engineering from Sichuan University in July 2003, a Master's degree in Leather Chemistry and Engineering from Sichuan University in June 2006, and subsequently obtained his Ph.D. in Engineering (Light Industry Technology and Engineering, Biomass Chemical Engineering) from Sichuan University in June 2011.

Dr. Lin has entered into a letter of appointment with the Company commencing from 27 March 2026 for a term of three years, and will continue thereafter until terminated by either party in accordance with the terms thereof (subject to re-election as and when required under the memorandum and articles of association of the Company and the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")). He will be entitled to an annual director's remuneration of HKD180,000, which was recommended by the Remuneration Committee of the Company with reference to his background, experience and level of responsibilities to be undertaken with the Company and the prevailing market conditions, and determined by the Board.

As at the date of this announcement, Dr. Lin has confirmed (i) his independence as regards each of the factors referred to in Rules 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interests in the business of the Company or its subsidiaries and does not have any connection with any of the Company's core connected persons (as defined in the Listing Rules); and (iii) there are no other factors which might affect his independence. As at the date of this announcement, other than disclosed above, Dr. Lin (i) does not hold any position with the Company and other members of the Group; (ii) does not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (iii) does not have any relationships with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) does not have any interest in shares of the Company and its associated corporations which is required to be disclosed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). There is no other matter relating to the appointment of Dr. Lin that needs to be brought to the attention of the Shareholders and there is no other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rule.

**(2) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board announces that on 27 March 2026, Mr. Cao resigned from the positions of Independent Non-Executive Director, Chairman of the Remuneration Committee, Member of the Audit Committee, Member of the Nomination Committee and Member of the Strategic Investment Committee of the Company, in order to devote more time to his personal commitments.

Mr. Cao has confirmed to the Company that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Cao for his valuable contributions to the Company during his tenure of service and welcome Dr. Lin for joining the Board.

By Order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**FU Haishu**  
*Chairman and Executive Director*

Hangzhou, the PRC, 27 March 2026

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Dr. Lin Hai, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-Executive Directors.*